ATS 2021 will feature presentations of original research from accepted abstracts. Mini Symposia and Thematic Poster Sessions are abstract based sessions.
Please use the form below to browse scientific abstracts and case reports accepted for ATS 2021. Abstracts presented at the ATS 2021 will be published in the Online Abstract Issue of the American Journal of Respiratory and Critical Care Medicine, Volume 203, May 3, 2021.
Search Tips:
- Use the keyword search to search by keyword or author's name.
- Filter your search results by selecting the checkboxes that apply.
- Click on "Clear" to clear the form and start a new search. .
Search results will display below the form.
Anxiety, Depressive Symptoms, and Attitudes About COVID-19 in Patients with Chronic Obstructive Pulmonary Disease
Session Title
TP22 - TP022 IMPACT OF SARS-COV-2 INFECTION IN PULMONARY MEDICINE: TRANSMISSION PREVENTION, IMPACT ON CHRONIC RESPIRATORY DISEASE, AND TREATMENT
Abstract
A1766 - Anxiety, Depressive Symptoms, and Attitudes About COVID-19 in Patients with Chronic Obstructive Pulmonary Disease
Author Block: K. Sumino1, S. L. Labedz2, A. J. Gangemi3, M. Zantah4, W. Z. Zhang5, R. A. Wise6, J. T. Holbrook7, For the American Lung Association-Airway ClinicalResearch Centers; 1Washington Univ in St Louis, St. Louis, MO, United States, 2University of Illinois at Chicago, Chicago, IL, United States, 3Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States, 4Pulmonary and Critical Care, Temple University Hospital, Philadelphia, PA, United States, 5Internal Medicine - Division of Pulmonary and Crtical Care, New York Presbyterian - Weill Cornell Medicine, New York, NY, United States, 6Johns Hopkins Univ, Baltimore, MD, United States, 7Bloomberg School of Public Health, Johns Hopkins Univ, Baltimore, MD, United States.
Rationale: Patients with chronic lung disease, such as chronic obstructive pulmonary disease (COPD), are at higher risk for severe COVID-19 disease. This study evaluated the anxiety and depressive symptoms, and attitudes about COVID-19 in a well-characterized group of patients with COPD enrolled in the Losartan Evaluation for Emphysema (LEEP) trial. Methods: This is an ancillary study of an ongoing LEEP trial evaluating the effect of losartan versus placebo on emphysema progression. From June 2017 to February 2020, 220 participants were enrolled in the 48-week LEEP trial. The main eligibility criteria were FEV1/FVC ratio<70% and FEV1 20-80%, >10 pack-year smoking, and a high resolution CT scan with 5-35% voxel with density <-950 Hounsfield Unit. From May 2020 to November 2020, 156 former and current LEEP participants participated in an ancillary study to evaluate the impact of COVID-19. Participants were interviewed by telephone every 2 months about their functional status and mental health using standardized, validated questionnaires; COPD Assessment Test (CAT), Generalized Anxiety Disorder-7 (GAD7) and the Patient Health Questionnaire-8 (PHQ-8). In addition, participants were asked about their experiences, knowledge, and attitudes about the pandemic. Measurements and Main results: Characteristics of the 156 participants at trial enrollment were median age of 66 y/o, 55% male, 82% white, 70% reported relying on public insurance and the median FEV1 was 48%. At the first interview, a small proportion (13%) had elevated scores for anxiety (GAD7>9) and 18% had elevated scores for depression (PHQ-8>9), which was similar to the prevalence in another COPD cohort evaluated prior to the pandemic. Regardless, 57% report significant concern that COVID-19 may affect their COPD. The large majority reported practicing recommended infection control measurements and 72% reported staying home more. The majority, 66%, said they were unlikely to receive a vaccine for COVID-19 (prior to the announcement of results of first vaccine trials). Trusted sources of information about the pandemic were doctors and healthcare providers (70%), followed by local news stations (70%), and CDC (61%). Most of the participants had good understanding of the symptoms and mode of transmission route of COVID-19. Conclusion: There was no increase in symptoms of anxiety or depression in patients with moderate-to-severe COPD associated with the pandemic; the prevalence of elevated anxiety and depression were relatively low. Most followed recommended infection control measures. The majority were concerned about the potential effects of COVID-19 on COPD disease.
Author Block: K. Sumino1, S. L. Labedz2, A. J. Gangemi3, M. Zantah4, W. Z. Zhang5, R. A. Wise6, J. T. Holbrook7, For the American Lung Association-Airway ClinicalResearch Centers; 1Washington Univ in St Louis, St. Louis, MO, United States, 2University of Illinois at Chicago, Chicago, IL, United States, 3Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States, 4Pulmonary and Critical Care, Temple University Hospital, Philadelphia, PA, United States, 5Internal Medicine - Division of Pulmonary and Crtical Care, New York Presbyterian - Weill Cornell Medicine, New York, NY, United States, 6Johns Hopkins Univ, Baltimore, MD, United States, 7Bloomberg School of Public Health, Johns Hopkins Univ, Baltimore, MD, United States.
Rationale: Patients with chronic lung disease, such as chronic obstructive pulmonary disease (COPD), are at higher risk for severe COVID-19 disease. This study evaluated the anxiety and depressive symptoms, and attitudes about COVID-19 in a well-characterized group of patients with COPD enrolled in the Losartan Evaluation for Emphysema (LEEP) trial. Methods: This is an ancillary study of an ongoing LEEP trial evaluating the effect of losartan versus placebo on emphysema progression. From June 2017 to February 2020, 220 participants were enrolled in the 48-week LEEP trial. The main eligibility criteria were FEV1/FVC ratio<70% and FEV1 20-80%, >10 pack-year smoking, and a high resolution CT scan with 5-35% voxel with density <-950 Hounsfield Unit. From May 2020 to November 2020, 156 former and current LEEP participants participated in an ancillary study to evaluate the impact of COVID-19. Participants were interviewed by telephone every 2 months about their functional status and mental health using standardized, validated questionnaires; COPD Assessment Test (CAT), Generalized Anxiety Disorder-7 (GAD7) and the Patient Health Questionnaire-8 (PHQ-8). In addition, participants were asked about their experiences, knowledge, and attitudes about the pandemic. Measurements and Main results: Characteristics of the 156 participants at trial enrollment were median age of 66 y/o, 55% male, 82% white, 70% reported relying on public insurance and the median FEV1 was 48%. At the first interview, a small proportion (13%) had elevated scores for anxiety (GAD7>9) and 18% had elevated scores for depression (PHQ-8>9), which was similar to the prevalence in another COPD cohort evaluated prior to the pandemic. Regardless, 57% report significant concern that COVID-19 may affect their COPD. The large majority reported practicing recommended infection control measurements and 72% reported staying home more. The majority, 66%, said they were unlikely to receive a vaccine for COVID-19 (prior to the announcement of results of first vaccine trials). Trusted sources of information about the pandemic were doctors and healthcare providers (70%), followed by local news stations (70%), and CDC (61%). Most of the participants had good understanding of the symptoms and mode of transmission route of COVID-19. Conclusion: There was no increase in symptoms of anxiety or depression in patients with moderate-to-severe COPD associated with the pandemic; the prevalence of elevated anxiety and depression were relatively low. Most followed recommended infection control measures. The majority were concerned about the potential effects of COVID-19 on COPD disease.
